Dynamic Advisor Solutions LLC Grows Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Dynamic Advisor Solutions LLC grew its position in DexCom, Inc. (NASDAQ:DXCM) by 34.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,235 shares of the medical device company’s stock after acquiring an additional 1,333 shares during the quarter. Dynamic Advisor Solutions LLC’s holdings in DexCom were worth $357,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Azzad Asset Management Inc. ADV purchased a new position in shares of DexCom in the first quarter valued at approximately $293,000. Marshall Financial Group LLC lifted its position in DexCom by 6.9% during the first quarter. Marshall Financial Group LLC now owns 14,142 shares of the medical device company’s stock worth $966,000 after buying an additional 907 shares in the last quarter. Union Bancaire Privee UBP SA lifted its position in DexCom by 100.2% during the first quarter. Union Bancaire Privee UBP SA now owns 6,005 shares of the medical device company’s stock worth $410,000 after buying an additional 3,005 shares in the last quarter. GPS Wealth Strategies Group LLC lifted its position in DexCom by 103.0% during the first quarter. GPS Wealth Strategies Group LLC now owns 3,222 shares of the medical device company’s stock worth $220,000 after buying an additional 1,635 shares in the last quarter. Finally, Fifth Third Bancorp lifted its position in DexCom by 1.0% during the first quarter. Fifth Third Bancorp now owns 31,656 shares of the medical device company’s stock worth $2,162,000 after buying an additional 309 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Cfra Research upgraded DexCom to a “hold” rating in a research report on Friday, March 21st. Truist Financial started coverage on DexCom in a research note on Monday. They set a “buy” rating and a $102.00 target price for the company. Mizuho started coverage on DexCom in a research note on Thursday, April 10th. They set an “outperform” rating and a $85.00 target price for the company. Piper Sandler cut their target price on DexCom from $100.00 to $90.00 and set an “overweight” rating for the company in a research note on Friday, May 2nd. Finally, Canaccord Genuity Group raised their target price on DexCom from $103.00 to $106.00 and gave the stock a “buy” rating in a research note on Friday, May 2nd. Four research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $98.50.

DexCom Trading Down 1.0%

DXCM opened at $81.01 on Friday. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $117.27. The stock has a market capitalization of $31.76 billion, a price-to-earnings ratio of 60.46, a PEG ratio of 1.73 and a beta of 1.46. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. The business has a fifty day moving average price of $79.80 and a 200 day moving average price of $79.40.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period in the previous year, the firm earned $0.32 earnings per share. The company’s revenue for the quarter was up 12.5% compared to the same quarter last year. Sell-side analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In other DexCom news, Director Nicholas Augustinos sold 2,618 shares of DexCom stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $81.69, for a total transaction of $213,864.42. Following the completion of the sale, the director now directly owns 37,083 shares of the company’s stock, valued at $3,029,310.27. The trade was a 6.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Sadie Stern sold 6,184 shares of DexCom stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total value of $526,320.24. Following the sale, the executive vice president now directly owns 109,621 shares of the company’s stock, valued at $9,329,843.31. This trade represents a 5.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 25,724 shares of company stock valued at $2,157,034 in the last three months. 0.32% of the stock is owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.